Mechanism of Action for NNZ-2566 Anti-inflammatory Effects Following PBBI Involves Upregulation of Immunomodulator ATF3

@article{Cartagena2013MechanismOA,
  title={Mechanism of Action for NNZ-2566 Anti-inflammatory Effects Following PBBI Involves Upregulation of Immunomodulator ATF3},
  author={C. Cartagena and K. L. Phillips and Garry L. Williams and Melissa Konopko and F. Tortella and J. Dave and Kara E. Schmid},
  journal={NeuroMolecular Medicine},
  year={2013},
  volume={15},
  pages={504-514}
}
  • C. Cartagena, K. L. Phillips, +4 authors Kara E. Schmid
  • Published 2013
  • Biology, Medicine
  • NeuroMolecular Medicine
    • The tripeptide glycine–proline–glutamate analogue NNZ-2566 (Neuren Pharmaceuticals) demonstrates neuroprotective efficacy in models of traumatic brain injury. In penetrating ballistic-like brain injury (PBBI), it significantly decreases injury-induced upregulation of inflammatory cytokines including TNF-α, IFN-γ, and IL-6. However, the mechanism by which NNZ-2566 acts has yet to be determined. The activating transcription factor-3 (ATF3) is known to repress expression of these inflammatory… CONTINUE READING
    View on Springer
    zenodo.org
    19 Citations
    Background Citations
    7
    19 Citations
    Citation Type

    Citation Type

    The role for IGF-1-derived small neuropeptides as a therapeutic target for neurological disorders
    • 20
    Neuroprotection with Glycine-2-Methylproline-Glutamate (G-2MePE) after hypoxic-ischemic brain injury in adult rats
    • PDF
    Microglial Inflammasome Activation in Penetrating Ballistic-Like Brain Injury.
    • 33
    Activating transcription factor 3, an early cellular adaptive responder in ischemia/reperfusion-induced injury
    • H. Lin, C. Cheng
    • Medicine
    • Ci ji yi xue za zhi = Tzu-chi medical journal
    • 2018
    • 2
    The role of microglial inflammasome activation in pyroptotic cell death following penetrating traumatic brain injury
    • 24
    Treatment of traumatic brain injury with anti-inflammatory drugs
    • 69
    Pharmacotherapy for Fragile X Syndrome: Progress to Date
    • 24
    Targeted treatments in fragile X syndrome
    • 7
    Fragile X targeted pharmacotherapy: lessons learned and future directions
    • 56
    Retracted: Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566
    • 6

    References

    SHOWING 1-10 OF 56 REFERENCES
    NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats
    • 62
    NNZ-2566, a glypromate analog, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury.
    • 39
    NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke
    • 23
    Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro.
    • 50
    Negative Regulation of TLR-Signaling Pathways by Activating Transcription Factor-31
    • 186
    • PDF
    Astrocytes produce and release interleukin-1, interleukin-6, tumor necrosis factor alpha and interferon-gamma following traumatic and metabolic injury.
    • 241
    Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4
    • 665
    • PDF
    Cortical injury increases cholesterol 24S hydroxylase (Cyp46) levels in the rat brain.
    • 44
    Distinct cellular patterns of upregulated chemokine expression supporting a prominent inflammatory role in traumatic brain injury.
    • 134
    T-cell cytokines in injury-induced neural damage and repair
    • 78